Medical authorities have issued a renewed safety alert concerning a rare but potentially serious complication associated with popular GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Mounjaro. The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its guidance to ensure both healthcare professionals and patients remain vigilant for symptoms of severe pancreatitis.
Regulatory Alert for Millions of Users
The MHRA's latest communication serves as an important reminder about a known but infrequent risk. While the agency has previously acknowledged the potential for pancreatitis development in those taking GLP-1 medications, this fresh warning emphasises the need for continued awareness. Recent research from University College London estimates that approximately 1.6 million adults across England, Scotland, and Wales used these drugs for weight management between early 2024 and early 2025.
Understanding the Pancreatitis Risk
The pancreas, a vital organ situated behind the stomach that aids digestion, can become dangerously inflamed. This condition, known as acute pancreatitis, manifests as intense, persistent abdominal pain that may radiate to the back and can be accompanied by nausea and vomiting. Although most patients recover within about a week, severe cases can lead to serious complications requiring urgent medical intervention.
Alison Cave, the MHRA's Chief Safety Officer, stated: "Patient safety is the MHRA's top priority. For the vast majority of patients, GLP-1s are safe and effective medicines delivering significant health benefits. However, the risk, though very small, necessitates awareness. We advise anyone experiencing severe, persistent stomach pain with these medications to consult a healthcare professional immediately and report it via our Yellow Card scheme."
Drug Authorisations and Usage
It is important to distinguish the licensed uses of these medications. Wegovy and Mounjaro are authorised specifically for weight loss management. Ozempic is licensed primarily for treating type 2 diabetes and for reducing cardiovascular risk in patients with established heart disease and a BMI of 27 or more. The MHRA clarified that GLP-1 receptor agonists are prescribed for type 2 diabetes and, for specific products, weight management and cardiovascular risk reduction.
Recognising the Symptoms
According to NHS guidance, the most common symptoms of acute pancreatitis include:
- Sudden onset of severe pain in the centre of the abdomen
- Feeling or being sick (nausea and vomiting)
- A high temperature of 38°C or more (fever)
The NHS advises seeking immediate medical attention from a GP if severe abdominal pain develops suddenly. If this is not possible, contacting NHS 111 for guidance is recommended.
The MHRA has now formally updated the product information for these drugs to reinforce awareness of this potential side effect among both prescribers and patients. This action underscores the ongoing pharmacovigilance process for all licensed medicines in the UK, balancing their proven benefits with transparent communication about potential risks.
